Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene.
Two members of a family previously classified as type 1 von Willebrand disease (VWD), showed a quantitative defect in von Willebrand factor (VWF) antigen and ristocetin cofactor activity and an abnormal capacity of VWF to bind FVIII. Sequencing of the VWF gene region coding for the FVIII binding domain revealed the most frequent type 2N mutation: a single nucleotide change (G2811A) in exon 20, resulting in substitution of glutamine (Gln) for arginine (Arg) 91 in the mature VWF protein in one allele. The other allele contained a cytosine deletion (2680delC) in exon 18, introducing a premature stop codon at position 79 (Val79X) which produced a quantitative defect in VWF levels. The Arg91Gln defect is usually not evident in heterozygotes; however, in these patients it was expressed due to the lack of VWF production from the other allele. This is the first report of type 2N VWD in Italy.
Casonato
A
A
University of Padua Medical School, Institute of Medical Semeiotics, Second Chair of Internal Medicine, Italy.
Gaucher
C
C
Pontara
E
E
Zucchetto
A
A
Zerbinati
P
P
Mazurier
C
C
Girolami
A
A
D001120:Arginine / Q000235:genetics; D003596:Cytosine; D005091:Exons; D005260:Female; D017353:Gene Deletion; D006474:Hemorrhagic Disorders / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D010375:Pedigree; D017354:Point Mutation; D014842:von Willebrand Diseases / Q000235:genetics*; D014841:von Willebrand Factor / Q000235:genetics*
D014841:von Willebrand Factor; D003596:Cytosine; D001120:Arginine